annual CFF:
$124.81M-$198.00K(-0.16%)Summary
- As of today (May 29, 2025), SRPT annual cash flow from financing activities is $124.81 million, with the most recent change of -$198.00 thousand (-0.16%) on December 31, 2024.
- During the last 3 years, SRPT annual CFF has fallen by -$436.76 million (-77.78%).
- SRPT annual CFF is now -85.95% below its all-time high of $888.08 million, reached on December 31, 2017.
Performance
SRPT Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$12.47M-$36.52M(-74.54%)Summary
- As of today (May 29, 2025), SRPT quarterly cash flow from financing activities is $12.47 million, with the most recent change of -$36.52 million (-74.54%) on March 1, 2025.
- Over the past year, SRPT quarterly CFF has dropped by -$9.67 million (-43.67%).
- SRPT quarterly CFF is now -97.73% below its all-time high of $549.25 million, reached on December 31, 2021.
Performance
SRPT quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$115.14M-$9.67M(-7.75%)Summary
- As of today (May 29, 2025), SRPT TTM cash flow from financing activities is $115.14 million, with the most recent change of -$9.67 million (-7.75%) on March 1, 2025.
- Over the past year, SRPT TTM CFF has increased by +$69.79 million (+153.89%).
- SRPT TTM CFF is now -87.51% below its all-time high of $921.87 million, reached on June 30, 2018.
Performance
SRPT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SRPT Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.2% | -43.7% | +153.9% |
| 3 y3 years | -77.8% | +149.9% | -79.6% |
| 5 y5 years | -80.6% | -96.1% | -80.3% |
SRPT Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -77.8% | at low | -94.2% | +3578.8% | -85.1% | +153.9% |
| 5 y | 5-year | -81.7% | at low | -97.7% | +3578.8% | -85.1% | +153.9% |
| alltime | all time | -86.0% | >+9999.0% | -97.7% | +152.1% | -87.5% | >+9999.0% |
SRPT Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $12.47M(-74.5%) | $115.14M(-7.7%) |
| Dec 2024 | $124.81M(-0.2%) | $48.99M(+256.1%) | $124.81M(+60.5%) |
| Sep 2024 | - | $13.76M(-65.5%) | $77.76M(-2.1%) |
| Jun 2024 | - | $39.92M(+80.3%) | $79.41M(+75.1%) |
| Mar 2024 | - | $22.14M(+1039.5%) | $45.35M(-63.7%) |
| Dec 2023 | $125.00M(-46.2%) | $1.94M(-87.4%) | $125.00M(-6.6%) |
| Sep 2023 | - | $15.40M(+162.8%) | $133.81M(-60.0%) |
| Jun 2023 | - | $5.86M(-94.2%) | $334.83M(+1.7%) |
| Mar 2023 | - | $101.80M(+847.0%) | $329.31M(+41.6%) |
| Dec 2022 | $232.51M(-58.6%) | $10.75M(-95.0%) | $232.51M(-69.8%) |
| Sep 2022 | - | $216.43M(>+9900.0%) | $771.01M(+37.6%) |
| Jun 2022 | - | $339.00K(-93.2%) | $560.48M(-0.6%) |
| Mar 2022 | - | $4.99M(-99.1%) | $563.67M(+0.4%) |
| Dec 2021 | $561.57M(-17.7%) | $549.25M(+9206.1%) | $561.57M(+65.5%) |
| Sep 2021 | - | $5.90M(+67.4%) | $339.26M(-3.7%) |
| Jun 2021 | - | $3.53M(+21.9%) | $352.14M(-3.8%) |
| Mar 2021 | - | $2.89M(-99.1%) | $366.19M(-46.3%) |
| Dec 2020 | $682.32M(+6.2%) | $326.94M(+1640.0%) | $682.32M(+11.4%) |
| Sep 2020 | - | $18.79M(+6.9%) | $612.35M(+2.9%) |
| Jun 2020 | - | $17.57M(-94.5%) | $595.30M(+1.9%) |
| Mar 2020 | - | $319.02M(+24.1%) | $584.01M(-9.1%) |
| Dec 2019 | $642.55M(+21.2%) | $256.97M(>+9900.0%) | $642.55M(-29.1%) |
| Sep 2019 | - | $1.73M(-72.5%) | $906.87M(+2.9%) |
| Jun 2019 | - | $6.29M(-98.3%) | $881.18M(-2.1%) |
| Mar 2019 | - | $377.56M(-27.6%) | $900.24M(+69.8%) |
| Dec 2018 | $530.15M(-40.3%) | $521.28M(-2276.1%) | $530.15M(+2.8%) |
| Sep 2018 | - | -$23.95M(-194.5%) | $515.68M(-44.1%) |
| Jun 2018 | - | $25.35M(+239.3%) | $921.87M(+3.0%) |
| Mar 2018 | - | $7.47M(-98.5%) | $895.35M(+0.8%) |
| Dec 2017 | $888.08M(+134.9%) | $506.81M(+32.6%) | $888.08M(+128.6%) |
| Sep 2017 | - | $382.24M(<-9900.0%) | $388.56M(+14.3%) |
| Jun 2017 | - | -$1.17M(-669.9%) | $340.03M(-10.4%) |
| Mar 2017 | - | $206.00K(-97.2%) | $379.37M(+0.3%) |
| Dec 2016 | $378.13M(+155.8%) | $7.29M(-97.8%) | $378.13M(-23.8%) |
| Sep 2016 | - | $333.71M(+774.3%) | $496.42M(+202.2%) |
| Jun 2016 | - | $38.17M(-3780.5%) | $164.28M(+12.2%) |
| Mar 2016 | - | -$1.04M(-100.8%) | $146.37M(-1.0%) |
| Dec 2015 | $147.81M(+41.9%) | $125.58M(+7868.0%) | $147.81M(+564.1%) |
| Sep 2015 | - | $1.58M(-92.2%) | $22.26M(-14.7%) |
| Jun 2015 | - | $20.25M(+4887.7%) | $26.09M(-74.4%) |
| Mar 2015 | - | $406.00K(+1591.7%) | $101.87M(-2.2%) |
| Dec 2014 | $104.16M(-28.5%) | $24.00K(-99.6%) | $104.16M(-1.8%) |
| Sep 2014 | - | $5.41M(-94.4%) | $106.10M(-55.7%) |
| Jun 2014 | - | $96.03M(+3470.0%) | $239.70M(+64.9%) |
| Mar 2014 | - | $2.69M(+36.9%) | $145.39M(-0.2%) |
| Dec 2013 | $145.67M(-18.4%) | $1.97M(-98.6%) | $145.67M(-51.6%) |
| Sep 2013 | - | $139.01M(+7977.5%) | $300.96M(+64.2%) |
| Jun 2013 | - | $1.72M(-42.1%) | $183.33M(+1.0%) |
| Mar 2013 | - | $2.97M(-98.1%) | $181.59M(+1.7%) |
| Dec 2012 | $178.60M(+452.9%) | $157.25M(+635.5%) | $178.60M(+737.7%) |
| Sep 2012 | - | $21.38M(<-9900.0%) | $21.32M(<-9900.0%) |
| Jun 2012 | - | -$21.00K(+5.0%) | -$50.00K(-100.2%) |
| Mar 2012 | - | -$20.00K(0.0%) | $32.18M(-0.4%) |
| Dec 2011 | $32.30M(+1200.3%) | -$20.00K(-281.8%) | $32.30M(-0.1%) |
| Sep 2011 | - | $11.00K(-100.0%) | $32.34M(-7.1%) |
| Jun 2011 | - | $32.21M(>+9900.0%) | $34.81M(+1238.9%) |
| Mar 2011 | - | $96.00K(+464.7%) | $2.60M(+4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | $2.48M(-94.8%) | $17.00K(-99.3%) | $2.48M(-0.6%) |
| Sep 2010 | - | $2.49M(>+9900.0%) | $2.50M(-92.3%) |
| Jun 2010 | - | $0.00(-100.0%) | $32.31M(+0.0%) |
| Mar 2010 | - | -$20.00K(-160.6%) | $32.30M(-32.4%) |
| Dec 2009 | $47.77M(<-9900.0%) | $33.00K(-99.9%) | $47.77M(+0.0%) |
| Sep 2009 | - | $32.30M(<-9900.0%) | $47.76M(+209.3%) |
| Jun 2009 | - | -$12.00K(-100.1%) | $15.44M(-0.2%) |
| Mar 2009 | - | $15.45M(>+9900.0%) | $15.48M(<-9900.0%) |
| Dec 2008 | -$32.00K(-100.2%) | $23.10K(-227.6%) | -$32.00K(-100.2%) |
| Sep 2008 | - | -$18.10K(-169.6%) | $18.62M(-0.1%) |
| Jun 2008 | - | $26.00K(-141.3%) | $18.64M(-0.2%) |
| Mar 2008 | - | -$63.00K(-100.3%) | $18.68M(-0.3%) |
| Dec 2007 | $18.74M(+129.6%) | $18.68M(>+9900.0%) | $18.75M(>+9900.0%) |
| Sep 2007 | - | $5200.00(-91.8%) | $141.90K(-6.5%) |
| Jun 2007 | - | $63.60K(>+9900.0%) | $151.70K(-20.9%) |
| Mar 2007 | - | $0.00(-100.0%) | $191.70K(-97.7%) |
| Dec 2006 | $8.16M(-81.2%) | $73.10K(+387.3%) | $8.16M(-72.1%) |
| Sep 2006 | - | $15.00K(-85.5%) | $29.24M(+0.1%) |
| Jun 2006 | - | $103.60K(-98.7%) | $29.22M(+0.1%) |
| Mar 2006 | - | $7.97M(-62.3%) | $29.19M(-32.9%) |
| Dec 2005 | $43.53M(+515.3%) | $21.15M(>+9900.0%) | $43.53M(+94.2%) |
| Sep 2005 | - | $0.00(-100.0%) | $22.41M(0.0%) |
| Jun 2005 | - | $68.00K(-99.7%) | $22.41M(+0.1%) |
| Mar 2005 | - | $22.31M(>+9900.0%) | $22.40M(+216.6%) |
| Dec 2004 | $7.07M(-79.8%) | $34.60K(>+9900.0%) | $7.07M(-66.3%) |
| Sep 2004 | - | $0.00(-100.0%) | $21.00M(-0.6%) |
| Jun 2004 | - | $53.50K(-99.2%) | $21.11M(-49.8%) |
| Mar 2004 | - | $6.99M(-49.9%) | $42.04M(+19.8%) |
| Dec 2003 | $35.08M(+59.6%) | $13.96M(>+9900.0%) | $35.08M(+63.6%) |
| Sep 2003 | - | $118.80K(-99.4%) | $21.44M(+0.6%) |
| Jun 2003 | - | $20.98M(>+9900.0%) | $21.30M(+5058.0%) |
| Mar 2003 | - | $26.20K(-91.8%) | $413.00K(-98.1%) |
| Dec 2002 | $21.98M(+104.2%) | $318.30K(-1868.3%) | $21.98M(+0.5%) |
| Sep 2002 | - | -$18.00K(-120.8%) | $21.86M(-1.5%) |
| Jun 2002 | - | $86.50K(-99.6%) | $22.19M(-31.4%) |
| Mar 2002 | - | $21.59M(>+9900.0%) | $32.35M(+200.6%) |
| Dec 2001 | $10.76M(-60.8%) | $204.00K(-34.7%) | $10.76M(+1.4%) |
| Sep 2001 | - | $312.60K(-96.9%) | $10.61M(-69.6%) |
| Jun 2001 | - | $10.24M(>+9900.0%) | $34.96M(+39.6%) |
| Mar 2001 | - | $6800.00(-87.4%) | $25.03M(-8.8%) |
| Dec 2000 | $27.44M(+234.6%) | $54.00K(-99.8%) | $27.44M(-22.9%) |
| Sep 2000 | - | $24.66M(+7773.7%) | $35.59M(+225.7%) |
| Jun 2000 | - | $313.20K(-87.0%) | $10.93M(+3.0%) |
| Mar 2000 | - | $2.41M(-70.6%) | $10.61M(+29.4%) |
| Dec 1999 | $8.20M(+4000.0%) | $8.20M(>+9900.0%) | $8.20M(>+9900.0%) |
| Sep 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 1999 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Dec 1998 | $200.00K(-98.9%) | $0.00(0.0%) | $200.00K(-77.8%) |
| Sep 1998 | - | $0.00(0.0%) | $900.00K(-67.9%) |
| Jun 1998 | - | $0.00(-100.0%) | $2.80M(-84.9%) |
| Mar 1998 | - | $200.00K(-71.4%) | $18.60M(+2.2%) |
| Dec 1997 | $18.20M(+366.7%) | $700.00K(-63.2%) | $18.20M(+4.0%) |
| Sep 1997 | - | $1.90M(-88.0%) | $17.50M(+12.2%) |
| Jun 1997 | - | $15.80M(-8000.0%) | $15.60M(-7900.0%) |
| Mar 1997 | - | -$200.00K | -$200.00K |
| Dec 1996 | $3.90M | - | - |
FAQ
- What is Sarepta Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Sarepta Therapeutics?
- What is Sarepta Therapeutics annual CFF year-on-year change?
- What is Sarepta Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly CFF year-on-year change?
- What is Sarepta Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM CFF year-on-year change?
What is Sarepta Therapeutics annual cash flow from financing activities?
The current annual CFF of SRPT is $124.81M
What is the all time high annual CFF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual cash flow from financing activities is $888.08M
What is Sarepta Therapeutics annual CFF year-on-year change?
Over the past year, SRPT annual cash flow from financing activities has changed by -$198.00K (-0.16%)
What is Sarepta Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SRPT is $12.47M
What is the all time high quarterly CFF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly cash flow from financing activities is $549.25M
What is Sarepta Therapeutics quarterly CFF year-on-year change?
Over the past year, SRPT quarterly cash flow from financing activities has changed by -$9.67M (-43.67%)
What is Sarepta Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SRPT is $115.14M
What is the all time high TTM CFF for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM cash flow from financing activities is $921.87M
What is Sarepta Therapeutics TTM CFF year-on-year change?
Over the past year, SRPT TTM cash flow from financing activities has changed by +$69.79M (+153.89%)